

# Lakeshore Isotopes

2727 West 21st St., Erie, PA 16505

RECEIVED

Phone: (814) 836-0207 Fax: (814) 836-0484

'04 DEC -2 A9:18

17 November, 2004

U. S. Nuclear Regulatory Commission Region I Office Chief, Nuclear Materials Safety Branch 475 Allendale Rd. King of Prussia, Penna. 19406

Dear Sirs -

03034217

We are a Nuclear Pharmacy operating in Erie, Penna. under NRC license number 37-28520-02MD and have recently relocated to 2727 W 21<sup>st</sup> St. Erie, Penna. Our former address was 4002 Schaper Ave., also in Erie. It was recently noticed during a license review that our latest license shows the correct 21<sup>st</sup> St. address, but still has the zip code for the old Schaper Ave. address. The zip code for our current address should be 16505; this is likely just a clerical error possibly on our part but we would like to correct it for the sake of completeness.

In another housekeeping matter, Maureen Bennett, R. Ph. is no longer employed by our company and therefore may be removed as an authorized user.

Our company has also recently undergone a change in management structure. I do not believe that this reorganization constitutes a change in control, however since our parent companies have both undergone substantial changes I felt it prudent to follow the form prescribed in NUREG 1556, vol. 15 anyway:

## DESCRIPTION OF TRANSACTION:

Prior to 1 September, 2004, Lakeshore Isotopes LLC operated two nuclear pharmacies, one at 2727 W. 21st St. in Erie and one at 110 Merchant Ln, Ste. B, Pittsburgh, Penna. The Erie pharmacy was known as Lakeshore Isotopes while the Pittsburgh pharmacy did business under the name Three Rivers Nuclear Pharmacy. Lakeshore Isotopes LLC was in turn owned jointly by Geodax Technologies, Inc. of Greensboro, N. C. and by Main Medical Inc. out of Pittsburgh, Penna. Main Medical was the major shareholder and provided virtually all management oversight.

Beginning on 1 September, Geodax Technologies began a merger with Cardinal Health Nuclear Pharmaceutical Services. Lakeshore Isotopes is NOT involved with this merger. Geodax Technologies' share in Lakeshore Isotopes LLC will rest with the former owners of Geodax (Dr. David L. Gilliland and Mr. George S. Gilliland) personally. Due to a non-compete clause binding the Gillilands, neither may participate in management of Lakeshore Isotopes LLC

> /36072 NM35/RGNI MATERIALS-002

in any way for the foreseeable future.

Also in September, the mobile nuclear businesses of Main Medical, Inc. were sold to a new company by the name of the Tomayko Group, LLC. The Tomayko Group is composed completely of former Main Medical, Inc. personnel and the Tomayko Group's CEO is Main Medical's former CEO, Dr. John R. Tomayko. Main Medical's ownership interest in Lakeshore Isotopes LLC remains as it has been, but management responsibility for Lakeshore Isotopes LLC now rests with the Tomayko Group, specifically with Dr. Tomayko who was also ultimately responsible for Lakeshore Isotopes LLC management prior to the reorganizations described above.

As a part of this reorganization it was decided to cease using the Three Rivers Nuclear Pharmacy name for the Pittsburgh pharmacy and to establish a new d.b.a. name Northwest Diagnostics for it. The Erie pharmacy will continue to be known as Lakeshore Isotopes. It was also discovered that the name Northwest Regional Diagnostics is not on our articles of incorporation; it is unclear how it came to be our NRC licensee name but it too will no longer be used.

### CHANGES OF PERSONNEL:

There are no changes of personnel. Although the companies involved have changed, all personnel remain and all duties of personnel remain unchanged with the exception of the Gilliland brothers who will no longer provide any management oversight. The Gillilands' management role previous to reorganization was very minor so I believe this to be a negligible change. The RSO remains the same and there are no changes in authorized users other than the housekeeping changes referred to above.

### CHANGES OF LOCATION, EQUIPMENT AND PROCEDURES:

No changes of location, equipment or procedures are planned.

#### SURVEILLANCE RECORDS:

All required surveillance will continue unchanged. All records of such will continue to be maintained at either the Pittsburgh or Erie pharmacies as appropriate and as has been done in the past. All surveillance and records are reviewed at least quarterly by a contracted health physicist and our RSO. To the best of our knowledge all records and practices are current.

## DECOMMISSIONING AND RELATED TRANSFER OF RECORDS:

No facilities will be decommissioned and no records will need to be transferred.

#### TRANSFEREE'S COMMITMENT OF ABIDE BY TRANSFEROR'S COMMITMENTS:

Lakeshore Isotopes LLC and its two pharmacies have not changed in structure at all, only the parent companies have. Therefore, I believe that there is no transfer of license or control; however for completeness, Lakeshore Isotopes LLC will continue to be bound by and to faithfully discharge any and all commitments made related to its materials licenses regardless of the date of these commitments unless such commitment is specifically nullified at a later date by order of the NRC or other appropriate regulatory agency.

Lastly, as mentioned above, our NRC license lists Northwest Regional Diagnostics as our legal name but we recently discovered that this is not the case. It is unclear how or why the Northwest Regional Diagnostics name was ever put onto the license, but it would be helpful if the name could be changed to our legal name of Lakeshore Isotopes, LLC.

Thank you in advance for your assistance in these matters. Please contact me at our Erie facility at 814-836-0207 if needed.

Many thanks,

Peter Pekelnicky, R. Ph. Director of Pharmacy, Radiation Safety Officer

This is to acknowledge the receipt of your letter/application dated

11/17/2000 <u>*IIII7 Earp*</u>, and to inform you that the initial processing which includes an administrative review has been performed.

There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

136072 Your action has been assigned Mail Control Number When calling to inquire about this action, please refer to this control number. You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (RI) (6-96)

Sincerely, Licensing Assistance Team Leader

	: (FOR LFMS USE)
	: INFORMATION FROM LTS
BETWEEN:	:
	:
License Fee Management Branch, ARM	: Program Code: 02500
and	: Status Code: 0
Regional Licensing Sections	: Fee Category: 3C 2B
	: Exp. Date: 20120430
	: Fee Comments:
	: Decom Fin Assur Reqd: N

LICENSE FEE TRANSMITTAL

- A. REGION I
- 1. APPLICATION ATTACHED Applicant/Licensee: NORTHWEST REGIONAL DIAGNOSTICS Received Date: 20041202 Docket No: 3034217 Control No.: 136072 License No.: 37-28520-02MD Action Type: Amendment
- 2. FEE ATTACHED Amount: Check No.:
- 3. COMMENTS

M. a. berlins 12/5/2004 Signed \_ Date

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /\_\_/)

1. Fee Category and Amount: \_\_\_\_\_

2. Correct Fee Paid. Application may be processed for: Amendment \_\_\_\_\_\_\_ Renewal \_\_\_\_\_\_

- License
- 3. OTHER

Signed \_\_\_\_\_\_ Date \_\_\_\_\_